Nature· 2026Q1
A multi-agent system for automating scientific discovery
- 151citations
- Q1SCImago
- 2026year
Short summary
Robin, a novel multi-agent AI system, fully automates hypothesis generation and data analysis for experimental biology, successfully identifying ripasudil and KL001 as potential therapeutic candidates for dry age-related macular degeneration (dAMD).
AI-generated from the title and abstract; the full text is not read.
Key points
- Robin is the first multi-agent AI system to fully automate hypothesis generation and data analysis in experimental biology.
- The system successfully identified ripasudil and KL001 as potential treatments for dry age-related macular degeneration (dAMD).
- Robin proposed enhancing retinal pigment epithelium phagocytosis as a therapeutic strategy for dAMD.
- A follow-up RNA-seq experiment, also proposed and analyzed by Robin, revealed ABCA1 upregulation as a potential mechanism for ripasudil's efficacy.
- All hypotheses, experimental directions, data analyses, and figures in the main text were generated by Robin.
AI-generated from the title and abstract; the full text is not read.
Abstract
Scientific discovery is driven by the iterative process of observation, hypothesis generation, experimentation, and data analysis. Despite recent advancements in applying artificial intelligence to biology, no system has yet automated all these stages [1, 2, 3]. Here, we introduce Robin, the first multi-agent system capable of fully automating both hypothesis generation and data analysis for experimental biology. By integrating literature search agents with data analysis agents, Robin can generate hypotheses, propose experiments, interpret experimental results, and generate updated hypotheses, achieving a semi-autonomous approach to scientific discovery. By applying this system, we were able to identify promising therapeutic candidates for dry age-related macular degeneration (dAMD), the major cause of blindness in the developed world [4, 5]. Robin proposed enhancing retinal pigment epithelium phagocytosis as a therapeutic strategy, and identified and confirmed in vitro efficacy for ripasudil and KL001. Ripasudil is a clinically-used Rho kinase (ROCK) inhibitor that has never previously been proposed for treating dAMD. To elucidate the mechanism of ripasudil-induced upregulation of phagocytosis, Robin then proposed and analyzed a follow-up RNA-seq experiment, which revealed upregulation of ABCA1 , a lipid efflux pump and possible novel target. All hypotheses, experimental directions, data analyses, and data figures in the main text of this report were produced by Robin. As the first AI system to autonomously discover and validate novel therapeutic candidates within an iterative lab-in-the-loop framework, Robin establishes a new paradigm for AI-driven scientific discovery.
The authors' abstract, as published at the source. Nature, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Drug DiscoveryPharmacology, Toxicology and Pharmaceutics